Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Shareholder Meeting (November 2025)
24 slides from Neurizon Therapeutics's shareholder meeting presentation, Nov 26, 2025
Slide 1: Shaping the future of neurodegenerative diseases
For personal use only Shaping the future of neurodegenerative diseases Dr Michael Thurn, Managing Director & Chief Executive Officer AGM CEO Presentation November 2025 ABN 35 094 006 023
Slide 2: Disclaimer
Disclaimer For personal use only This disclaimer applies to this presentation and the information contained in it (This presentation has been Future Matters prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective in
Slide 3: Our Vision
For personal use only Our Vision To lead the development of neurodegenerative treatments towards a promising new horizon for patients.
Slide 4: Our Promise
Accelerating Patient Driving Hope and Access to Clinical For personal use only Innovative ALS Our Promise Treatment Progress Unlocking the potential Delivering commercial of Neurizon to address readiness and high unmet need in stakeholder neurodegenerative value diseases
Slide 5: Our Promise (detail)
Accelerating Patient Hope and Access to Driving Clinical Progress Innovative ALS Treatment We are committed to making therapies available as early Our lead candidate, NUZ-001, is being developed for neurodegenerative diseases and has been selected for For personal use only as possible through regula
Slide 6: Neurizon & The Science Behind It
For personal use only Neurizon & The Science Behind It
Slide 7: From Humble Beginnings
From Humble Beginnings Scientific reappraisal of an approved veterinary product uncovered a new pharmacology for neurodegenerative disease Potential Platform Therapy For personal use only NUZ-001 for Neurodegenerative Antihelminth Phase 1 ALS POC Diseases Approved Anticancer Autophagy Activator Meth
Slide 8: Our Strategic Progress
Our Strategic Progress Initial focus is on advancing clinical work on ALS, through HEALEY ALS Platform Trial participation For personal use only Drug / Approved/ Next Major Partnerships & Licensing Indication Preclinical Phase 1 Phase 2 Phase 3 Dosage Form Marketed Catalysts Accelerated • Regimen Sp
Slide 9: Amyotrophic Lateral Sclerosis: Urgent need for life-changing therapies
Amyotrophic Lateral Sclerosis Urgent need for life-changing therapies For personal use only Neurodegenerative disorder that primarily affects motor neurons, typically fatal within 2-5 years of symptom onset, with currently no disease modifying therapeutics on the market. This is in part due to the c
Slide 10: TDP-43 Aggregates are a Hallmark of ALS Pathology
TDP-43 Aggregates are a Hallmark of ALS Pathology Protein aggregates are cleared by multiple pathways including autophagy-lysosomal and ubiquitin-proteasome systems. Together these systems help to maintain proteostasis For personal use only ALS Patient Population1 Spinal Cord Clearance of misfolded
Slide 11: Open Label Extension Survival Probability Analysis
Phase 1 Open Label Extension Survival Probability Analysis For personal use only Compared to matched controls from the PRO-ACT, treatment with NUZ-001 results in a significantly (X2=13.75, p=0.00021) longer survival of patients with ALS > Doubling Life Expectancy (X2=13.75, p=0.00021) Reduction in t
Slide 12: Recent Value-Building Milestones
Demonstrating Meaningful Progress: Recent Value-Building Milestones For personal use only Executed NUZ-001 IND First Preliminary Australian Global License Opened, clearing registration R&D Funding Patent Agreement the path to batch of received granted for with Elanco HEALEY NUZ-001 NUZ-001 PACTALS &
Slide 13: Entering The Next Phase Of Value Creation: HEALEY ALS Platform Trial
For personal use only Entering The Next Phase Of Value Creation: HEALEY ALS Platfrom Trial
Slide 14: HEALEY ALS Platform Trial
HEALEY ALS Platform Trial NUZ-001 selected for entry into the HEALEY ALS Platform Trial HEALEY ALS Platform Trial is a competitive process led by a group of expert ALS scientists and members of the Healey Science Advisory Committee For personal use only HEALEY ALS Platform Trial Design1 Innovative T
Slide 15: HEALEY ALS Platform Trial Regimen I for NUZ-001
HEALEY ALS Platform Trial Regimen “I” for NUZ-001 36-week Double blind Placebo 36-week Active Treatment Screening Period Controlled Period Extension Period For personal use only NUZ-001 10 mg/kg Biomarkers DNA ALSFRS-R 3:1 Randomization NUZ-001 n=160 patients 10 mg/kg Placebo Primary Endpoint • Chan
Slide 16: Regimen-I HEALEY ALS Platform Trial Key Milestones
“Regimen-I” HEALEY ALS Platform Trial Key Milestones IND Amendment Submission Q4 2025 1 Platform Trial IND submitted to regulatory authorities For personal use only Neurizon’s clinical hold FDA Clearance 2 Q4 2025 NUZ-001 entry confirmed was lifted by the FDA on October 3, 2025, clearing First Patie
Slide 17: Accelerated & Streamlined Path to NDA and Launch
Accelerated & Streamlined Path to NDA and Launch Elanco License Agreement For personal use only Sample 5 • Strengthens NDA readiness MODULE 5 Elanco License • Reduces development cost Text Clinical Agreement • Supports accelerated timeline & launch readiness Sample 4 MODULE 4 01 Comprehensive non- 0
Slide 18: Capital Management
For personal use only Capital Management
Slide 19: Corporate Overview
Corporate Overview Mid-stage biotechnology company targeting human neurodegenerative diseases Share Price Performance Capital Structure (AUD$) 25 November 2025 For personal use only Current Share Price (NUZ/NUZOA) $0.11/ $0.026 Closing Price (AUD$) Volume (m) 52 Week Low / High (NUZ) $0. 096/ $0.19
Slide 20: HEALEY Funding Strategy
Capital Management HEALEY Funding Strategy The Board has undertaken an extensive review and is well advanced in evaluating funding alternatives. Neurizon expects to be able to confirm a For personal use only preferred funding solution, to support execution of the HEALEY ALS Platform Trial and ongoin
Slide 21: Case Study: Amylyx Pharmaceuticals
Case Study Amylyx Pharmaceuticals (NASDAQ:AMLX) ~US$2.5bn at For personal use only Accelerated Approval (+ 177%) Phase 3 PHOENIX commences Phase 2 CENTAUR Phase 2 CENTAUR OLE FDA OLE finishes commences Market Cap (US$’m) Approval Phase 2 CENTAUR Phase 2 CENTAUR $883m Relyvrio® (AMX0035) commences fi
Slide 22: Strengthening our global presence
Strengthening our global presence For personal use only
Slide 23: Near Term Milestones
Near Term Milestones Significant near-term news flow drive value and growth ✓ US FDA lifts clinical hold For personal use only ✓NEALS Annual Conference Meeting Presentations ✓Commenced trading on OTCQB ✓Australian Patent granted for NUZ-001 • HEALEY ALS Platform Trial– Site Activation ✓HEALEY Submit
Slide 24: Our Mission
For personal use only Our Mission To create hope by advancing innovative, disease- modifying therapies that deliver meaningful, science driven progress for people living with neurodegenerative diseases – with urgency, scientific excellence and deep commitment to the communities we serve
Neurizon Therapeutics — Shareholder Meeting (November 2025) on 6ix